90 results
6-K
EX-99.1
REPCF
Replicel Life Sciences Inc.
20 Mar 24
RepliCel announces a Letter of Intent for Asset Purchase Agreement
4:38pm
to approve the Proposed Transaction (the "Meeting"). The Proposed Transaction also has to be approved by an affirmative vote of at least a simple majority
6-K
EX-99.2
REPCF
Replicel Life Sciences Inc.
20 Mar 24
RepliCel announces a Letter of Intent for Asset Purchase Agreement
4:38pm
Transaction also has to be approved by an affirmative vote of at least a simple majority of the votes cast by shareholders of RepliCel present in person
6-K
EX-99.2
REPCF
Replicel Life Sciences Inc.
30 Nov 23
Condensed Consolidated Interim Financial Statements
1:05pm
of their duties to the Company, though such an action, if successful, might otherwise benefit the Company and its shareholders.
As a majority of the Company's … , any judgments obtained against the Company, directors and officers.
A majority of the Company's directors and officers are nationals and/or residents
6-K
EX-99.2
REPCF
Replicel Life Sciences Inc.
24 Oct 23
Condensed Consolidated Interim Financial Statements
11:10am
.
As a majority of the Company's directors and officers are residents of countries other than the United States, investors may find it difficult to enforce … , within the United States, any judgments obtained against the Company, directors and officers.
A majority of the Company's directors and officers
6-K
EX-99.2
REPCF
Replicel Life Sciences Inc.
30 Aug 23
Notice of Annual General and Special Meeting of Shareholders
5:15pm
, the vast majority of such Shares are registered under the name of Cede & Co. as nominee for The Depository Trust Company (which acts as depositary … of the Beneficial Shareholder. The majority of brokers now delegate responsibility for obtaining instructions from clients to Broadridge Financial Solutions, Inc
6-K
EX-99.2
fzytdjo2dk
30 May 23
Condensed Consolidated Interim Financial Statements
5:40pm
6-K
EX-99.2
wb7283n311grh71lnod
29 Nov 22
Condensed Consolidated Interim Financial Statements
6:44pm
20-F/A
jpjje06srxb djouqo
12 Sep 22
Annual report (foreign) (amended)
6:17pm
6-K
EX-99.2
2hrp3g5a
6 Sep 22
Condensed Consolidated Interim Financial Statements
12:42pm
6-K
EX-99.4
988do9uodr
7 Jul 22
RepliCel Provides Update on Private Placement
3:36pm
6-K
EX-99.2
iebe0vo
30 Nov 21
Condensed Consolidated Interim Financial Statements
1:50pm
6-K
EX-99.1
uw3y5l2 rsmm1w1m
18 Nov 21
Notice of Annual General and Special Meeting of Shareholders
10:36am
6-K
EX-99.2
mtp2w yah
31 Aug 21
Condensed Consolidated Interim Financial Statements
1:45pm
6-K
EX-99.2
xc052z7xzc m6f3cryl
1 Jun 21
Condensed Consolidated Interim Financial Statements
3:57pm
20-F/A
dvb7cmwzkkkb7p
31 Mar 21
Annual report (foreign) (amended)
12:00am
6-K
EX-99.3
6cb9z 22xae
3 Feb 21
RepliCel and MainPointe Pharmaceuticals Sign Strategic Investment and Collaboration Agreement
12:03pm